Farydak (panobinostat) / Secura Bio  >>  Phase 4
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Farydak (panobinostat) / Secura Bio
NCT02386800 / 2014-003527-22: CINC424A2X01B Rollover Protocol

Recruiting
4
356
Europe, Japan, RoW
ruxolitinib, INC424, Jakavi, panobinostat, LBH589, Farydak
Novartis Pharmaceuticals
Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia, Thalassemia
09/27
09/27

Download Options